Background and aims: The effects of maintenance infliximab for Crohn's disease vary widely among patients. The aim of this study was to examine the cytokine profiles and to identify possible markers predictive of therapeutic effect of maintenance infliximab. Methods: Cytokine profiles of 35 Crohn's disease patients under maintenance infliximab therapy were analyzed prospectively. Blood samples were obtained prior to, and 2 and 6 weeks after infliximab infusion. Circulating cytokine values of interleukin (IL)-23, IL-17A, IL-12, IL-6, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) were compared according to the disease activity and therapeutic efficacy. Patients were classified into either the active or quiescent phase according to their disease activity at baseline. Patients were also divided into a sustained response group and non-sustained response group according to therapeutic efficacy of infliximab determined 2 and 6 weeks after infliximab infusion. Results: At baseline, serum levels of IL-23 (p b 0.05), IL-17A (p b 0.01), IFN-γ (p b 0.05), and IL-6 (p b 0.01) were significantly higher in active Crohn's disease than in quiescent disease. These cytokine levels remained unchanged during the follow-up period. When serum cytokine levels were compared between groups classified by therapeutic efficacy of infliximab, patients in the nonsustained response group had a significantly higher level of serum IL-17A than those in the sustained response group (p b 0.05). There were also trends toward higher serum IL-23 and IL-12 in the former than in the latter. Conclusion: Higher levels of IL-17A, IL-23, and IL-12 at baseline may be predictive markers for poor therapeutic response to maintenance infliximab therapy.
Introduction
Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that plays an important role in the pathogenesis of Crohn's disease (CD). The striking therapeutic effects of infliximab (IFX), a chimeric monoclonal antibody to TNF-α, have led to dramatic success as a medical treatment for patients with fistulizing CD or refractory luminal CD. 1, 2 However, IFX is expensive and is associated with a high incidence of adverse events, including infusion reaction and infections. 3 Furthermore, the disease flares up in 30% of CD patients who receive treatment with scheduled IFX administration. 4 Thus, the identification of factors predictive for a therapeutic response is clinically important in terms of cost-effectiveness, attenuation of morbidity, and the improvement of response rates associated with IFX use.
Clinical variables, including smoking, 5 younger age, 6 disease duration, 7 concomitant use of immunomodulatory drugs, 5 the site of disease 5, 6 and the presence of intestinal stricture 8, 9 have been shown to be associated with the efficacy of IFX. Serological markers such as pANCA and ASCA, 10 and genetic factors including FCGR3A, 11 apoptosis-related genes, 12 ADAM17 locus 13 and IL23R genotypes, 14 have also been shown to be predictive of the effect of IFX. Although TNF-α, 15, 16 interleukin (IL)-6, and IL-1β, 15 have been suggested to be predictive factors, extensive analyses of cytokine profiles have not yet been performed among CD patients under maintenance IFX treatment.
There has been an accumulation of data indicating a close association of Th1/Th17 cytokines to the pathogenesis of the disease. [17] [18] [19] [20] In the present study, we assessed circulating cytokine levels, with a special reference to Th1/Th17 profile, before and after the administration of IFX to identify possible biomarkers predictive of the effect of maintenance IFX administration.
Materials and methods

Patients and study protocol
During the period between January 2007 and November 2008, 53 of 139 CD patients at our institution received maintenance IFX treatment. The diagnosis of CD was based on clinical, radiological, endoscopic, and pathological findings compatible with the disease. Written informed consent for the present study was obtained from 42 patients. Seven patients were excluded because of a delay in hospital visit (5 patients), failure of blood sampling (one patient), and loss to follow-up (one patient). The remaining 35 patients were the subjects included in the present investigation.
The subjects were prospectively followed for 6 weeks after a single infusion of IFX (5 mg/kg). All of the patients received a single dose of methylprednisolone (125 mg intravenously), acetaminophen (400 mg orally), and diphenhydramine (40 mg orally) prior to the administration of IFX so that the risk of an immediate infusion reaction could be minimized. The IFX treatment included scheduled administration in 32 patients and episodic administration in 3 patients. Blood samples for routine laboratory tests and cytokine analyses were obtained at baseline, and at 2 and 6 weeks after treatment.
Serum and plasma aliquots for cytokine measurement were stored at −80°C until the assay.
Blood samples of age-and sex-matched controls were also obtained for the present investigation after obtaining written informed consent. The control samples were used for the comparison of baseline cytokine values.
The study protocol was approved by the ethical committee at Kyushu University hospital, and the study was conducted in accordance with the Helsinki Declaration. During the investigation, no patient suffered from any adverse effect of IFX.
Assessment of disease activity and therapeutic effect of IFX
The disease activity at each observation was assessed according to Crohn's disease activity index (CDAI) 21 or the index of inflammatory bowel disease (IOIBD). 22 Patients with CDAI value less than 150 or with IOIBD less than 2 were considered to be in remission. Otherwise, the patients were deemed to have active disease. Based on the disease activity at baseline, patients were classified as having either active phase or quiescent phase disease.
Among the patients in the active phase, therapeutic efficacy of IFX was classified into two categories according to the disease activities 2 and 6 weeks after IFX infusion. Patients with CDAI value of less than 150 at the times of the assessment were defined as sustained responders (S-group). Patients who did not fulfill the above criteria were regarded as non-sustained responders (N-group). In patients with a colostomy or an ileostomy, patients with IOIBD of less than 2 at both assessments were classified as being in S-group. Otherwise, patients were classified as belonging to N-group.
Assay of circulating cytokine levels
Serum levels of IL-23 (IL-23p19p40), IL-17A, IL-12 (IL-12p70), IFN-γ, and IL-6 were measured using an enzyme linked immunosorbent assay (ELISA) (eBioscience; San Diego, USA) according to the manufacturer's instructions. The plasma TNF-α level was analyzed using quantitative sandwich enzyme immunoassays (Quantikine; R&D systems, Abingdon, UK). The sensitivity of the assays was 15 pg/ml for IL-23, 4 pg/ml for IL-17A, IL-12 and IFN-γ, 2 pg/ml for IL-6, and 0.55 pg/ml for TNF-α. When the values of the assay were under the lower limit of detection, the circulating cytokine levels were considered to be null. The measurement of each assay was performed in duplicate.
Statistical analysis
The parametric data were expressed as the mean ± standard error of the mean (SEM) or mean (range). Clinical characteristics among the groups were compared using χ 2 test and Student's t-test. Cytokine levels among the groups at each assessment were compared using the Mann-Whitney U test, and the levels before and after IFX treatment in each group were compared using the Wilcoxon signed-rank test. All of the statistical analyses were performed using the JMP7 software package (SAS Institute, Cary, NC, USA). A pvalue b 0.05 was regarded to be statistically significant. Table 1 indicates the clinical characteristics of the patients at baseline and controls. The patients were comprised of 24 males and 11 females, with a mean age of 32 years (range: 12-59 years). The mean duration of the disease was 10.5 years (range: 1-35 years). Eight patients showed fistulizing CD and 13 patients had undergone surgery. Before entry into the study, patients received IFX infusion from 3 times to 25 times with a mean of 7.4 times. During the maintenance IFX treatment, thiopurine was concomitantly administered to 18 patients and aminosalicylates to 29 patients. Fig. 1 shows patients' responses to IFX administration. At baseline, the mean value of CDAI was 156.1 (range; 36.6-359.7) in 29 patients without colostomy, and the mean value of IOIBD was 3.2 (range; 1-5) in 6 patients with colostomy. Accordingly, 20 patients were defined to be in the active phase, and the remaining 15 patients in the quiescent phase. Fifteen patients in the active phase achieved remission at 2 weeks after IFX administration, whereas the disease deteriorated in 7 patients at weeks 6. The disease was still in the active phase during 6 weeks' follow-up in 5 patients. Thus, 12 patients were regarded as being non-sustained responders (N-group). The therapeutic efficacy of IFX in the remaining 8 patients was sustained, and those patients were classified into S-group. Demographic characteristics of N-and S-groups were compared in Table 2 . Although no statistical difference was observed between the two groups, patients in S-group had younger age, shorter duration of disease, and less frequent history of previous surgery. In 15 patients in the quiescent phase at baseline, the disease was still in remission during the subsequent follow-up. Table 3 compares the circulating cytokine levels between CD patients at baseline and healthy subjects. When compared to healthy subjects, the levels of IL-23, IL-17A, IFN-γ, IL-6, and TNF-α were significantly higher in CD patients. Although the mean IL-12 level was higher in CD patients than in healthy subjects, the difference did not reach statistical significance.
Results
Demographic data and clinical course after IFX treatment
Circulating cytokine levels during follow-up
When we compared the cytokine values according to the disease activity at baseline, IL-23, IL-17A, IFN-γ and IL-6 were significantly higher in CD patients in the active phase than in those in the quiescent phase (Table 4) . Although IL-12 was higher and TNF-α was lower at baseline in patients in the active phase, the difference was not statistically (Table 4 ). When we compared serial changes in those cytokines in each group, the levels of IL-23, IL-17A, IL-12, IFN-γ, and IL-6 did not change after IFX administration. In contrast, the plasma TNF-α level increased at weeks 2 and 6 in patients in the active phase.
Comparison of cytokine levels between the sustained response and non-sustained response groups
We compared the circulating cytokine levels at baseline between N-and S-groups. As shown in Fig. 2 , there were 3 patients in N-group who showed extraordinary high levels of IL-23, IL-17A, and IL-12. The serum IL-17A level at baseline was significantly higher in N-group than in S-group (p = 0.04), while the differences in IL-23 (p = 0.28) and IL-12 (p = 0.32) between the two groups were not statistically significant (Table 5 ). Serum levels of neither IFN-γ (p = 0.32) nor IL-6 (p = 0.16) were different between the two groups. On the other hand, TNF-α was lower in N-group (p = 0.054), although the differences did not reach statistical significance (Table 5) . Table 5 shows the serial changes in the circulating cytokines in N-and S-groups. A significant increase in the plasma TNF-α level was found at week 6 in both S-group (p = 0.02) and N-group (p = 0.01). In contrast, the serum IL-6 levels at both week 2 and week 6 tended to be lower than at baseline in S-group (p = 0.09 and p = 0.13, respectively), although the serum IL-6 level at each assessment was similar in N-group. The serum levels of the other cytokines showed no significant changes after IFX administration.
Discussion
The anti-inflammatory effect of TNF-α inhibitors is derived from their inhibition of a variety of cytokines that exist downstream of the TNF-α cascade through their effect of neutralization of TNF-α and blockade of its effect. 23, 24 IFX exerts a further therapeutic effect by destroying monocytes 25 and lamina propria T-lymphocytes 26 by inducing their apoptosis, as well as by inducing cell lysis via complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. Therefore, it is possible that IFX affects the production of cytokines both downstream and upstream of the TNF-α cascade. In addition, close association of Th17 cytokines, including IL-17, IL-22, IL-23, and IL-26 with the pathogenesis of CD has been recently reported. [27] [28] [29] [30] Among various cytokines, we chose TNF-α, IFN-γ, IL-6, IL-12, IL-17A, and IL-23, and assessed the profile in CD patients under IFX treatment.
When compared to healthy subjects, CD patients under maintenance IFX treatment had significantly higher levels of TNF-α, IFN-γ, IL-6, IL-17A, and IL-23 prior to the administration of IFX. This finding is consistent with recent reports showing high levels of circulating TNF-α, 31 IL-6, 32 and IL-17 33 in CD patients. Elevated levels of IL-23p19 transcription and the increased expression of IL-23 of lamina propria mononuclear cells (LPMCs) have been also reported in CD patients. [34] [35] [36] However, there have not been any studies on the circulating IL-23 levels in CD patients. In the present study, we demonstrated, for the first time, that IL-23 is elevated in CD patients under maintenance IFX treatment.
In our CD patients, the circulating levels of IL-23, IL-17A, IFN-γ, and IL-6, but not TNF-α, were significantly higher in patients in the active phase than in those in the quiescent phase at baseline. These results were consistent with the previous reports indicating higher levels of IL-6 37 and IL-17 33 in patients with active CD without IFX treatment. It thus seems plausible that these circulating cytokines enhance the disease activity regardless of the types of medication being administrated. On the other hand, our results suggest that plasma TNF-α level is not associated with the disease activity under maintenance IFX treatment.
In the present study, we also analyzed serial changes in the circulating cytokines under maintenance IFX treatment. Although the difference was not statistically significant, there were trends towards lower serum IL-6 levels at weeks 2 and 6 than at baseline in patients in S-group. In consideration of a similar observation that serum IL-6 levels decreased until Data are shown as the mean ± SEM. Cytokine values of the two groups are compared using the Mann-Whitney U-test. Table 4 Serial changes of circulating cytokine levels of the two groups classified by the disease activity at the baseline.
Activity at baseline
Active phase Quiescent phase 01; values at each assessments are compared between the two groups using the Mann-Whitney U test. ⁎ p b 0.05; values are compared to those at baseline using the Wilcoxon signed-rank test. week 6 after IFX, 15 the inhibitory effect of IFX against IL-6 is presumed to be another pathway by which the drug exerts its therapeutic effects. On the other hand, no serial changes in IL-23, IL-17A, IL-12, or IFN-γ were found, regardless of the therapeutic effect of IFX. In addition, plasma TNF-α levels at weeks 2 and 6 were significantly higher than those at baseline in both N-and S-groups. Such an enigmatic change in TNF-α after IFX administration was also found in patients with rheumatoid arthritis 38 or juvenile idiopathic arthritis. 39 Furthermore, in contrast to other circulating cytokines, plasma TNF-α levels were insignificantly but slightly higher in S-group than in N-group at all time points of assessment. Although we have no additional data to explain this observation, we presume that serum IFX level and antibody to IFX (ATI) are associated with serum TNF-α level. It has been reported that serum TNF-α level was higher in subjects treated with 10 mg/kg of IFX than in those with 1 mg/kg of IFX. 38 It thus seems likely that serum TNF-α level is positively associated with the serum level of IFX. It can also be presumed that the higher titer of ATI results in lower serum IFX level. Taken these into consideration together, it seems probable that CD patients in N-group have a high titer of ATI, and as a consequence, low serum IFX and TNF-α levels, while a counterpart may be the case for CD patients of S-group.
Of interest, we identified 3 patients in N-group who had extremely high levels of IL-23, IL-17A, and IL-12 at baseline. Because these cytokines are located upstream of TNF-α in the cytokine cascade, the blockade of TNF-α may not be sufficient Figure 2 Comparison of cytokine levels at baseline between the two groups classified by their response of IFX treatment (S-group vs. N-group). The serum IL-17A level was significantly higher in the N-group than in the S-group. to decrease inflammation, thereby resulting in a poor therapeutic effect of IFX for such patients. Fuss et al. 35 have recently reported the downregulation of IL-23, IL-12p70, IL-17, and IL-6 syntheses by LPMCs in CD patients following the administration of an anti-IL-12/IL-23 p40 monoclonal antibody. In addition, a novel association between Th17 cell function and IL-23R genotype has been recently reported. 40, 41 Taken these together, an anti-IL-12/IL-23 p40 monoclonal antibody, rather than IFX, may be necessary for treating CD patients demonstrating higher levels of IL-23, IL-12, and IL-17A.
The present study has several limitations. First, we did not examine ATI and IFX concentrations in the present study. Since either ATI or IFX concentration has been shown to be relevant with the response to IFX, 42 the poor therapeutic effect of IFX in N-group may be partly explained by the presence of ATI or lower IFX concentration. However, since IFX in the blood sample interferes correct ATI assay, 43 neither ATI nor IFX concentration was measured in the present study. Second, methylprednisolone prior to IFX may have influenced cytokine levels. However, we believe the pretreatment to have affected little because blood samples at baseline were obtained prior to the pretreatment. Third, the number of patients enrolled for the present study was relatively small, that might also cause a type 2 error for the comparison of circulating cytokine levels between Nand S-groups. However, we believe that the present study is meaningful because this is the first prospective study that focused on circulating cytokines including IL-23 in CD patients under maintenance IFX treatment.
In conclusion, our results indicated that in patients with CD, higher levels of circulating proinflammatory cytokines demonstrated a close association with the disease activity and also with the therapeutic response to IFX. In particular, significantly higher levels of IL-23, IL-17A, and IL-12 appear to be possible predictive markers for a poor therapeutic response to IFX. In such cases, alternative treatments using ustekinumab, an anti-IL-12/IL-23 p40 monoclonal antibody, would be recommended. Although a recent CERTIFI trial failed to show better therapeutic efficacy of ustekinumab than IFX, a selection of patients preferable to ustekinumab by the assessment of circulating cytokine levels may become one of the tailor-made strategies for CD.
